Achilles Therapeutics plc

Achilles Therapeutics plc (ACHL) priced its initial public offering on Mar 31, 2021 at $18.00 per ADS, within its $17.00–$19.00 range, raising $175.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $731.2M. J.P. Morgan was lead-left underwriter, joined by BofA Securities, Piper Sandler and Chardan and others. Latham & Watkins advised the underwriters.

Achilles Therapeutics plc is a clinical-stage immuno-oncology company developing precision T cell therapies for solid tumors that target clonal neoantigens, mutations present in all of a patient's cancer cells but absent from healthy tissue. Its PELEUS bioinformatic platform uses data from the TRACERx study.

Status

IPO

Ticker

ACHL

Exchange

Nasdaq Global Select

Priced

Mar 31, 2021

IPO price

$18.00 per ADS

Price range

$17.00–$19.00

Raised

$175.5M

Market cap at IPO price

$731.2M

First filed

Mar 1, 2021

Underwriters

J.P. Morgan, BofA Securities, Piper Sandler, Chardan and Oppenheimer

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.